Lupin receives tentative approval from USFDA for Valbenazine capsules
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
Valbenazine Capsules (RLD Ingrezza) had estimated annual sales of USD 1,235 million in the U.S. (IQVIA MAT December 2022).
The company is addressing these observations
The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin’s marketed products worldwide
India has a pivotal role in eliminating TB
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation)
The patent was granted for creating a green catalyst for one of the world's most significant chemical reactions
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety
Obeticholic Acid Tablets (RLD Ocaliva) had estimated annual sales of US $255 million in the US (IQVIA MAT December 2022).
Integration of modern and traditional medicine to facilitate the illness to wellness journey
Essex enriches and complements Emmes’ services
Subscribe To Our Newsletter & Stay Updated